Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1991-11-29
|
pubmed:abstractText |
In order to determine an optimum mode for systemic administration of recombinant interleukin 2 (rIL2), the effects of rIL2 on lymphocyte-mediated cytotoxicity against renal carcinoma cells were studied in vitro. Augmentation of the cytotoxicity by rIL2 was dose- and time-dependent. The optimum dose of rIL2 was 100-500 units (Jurkat units)/ml, and cytotoxicity increased significantly even at a low concentration such as 4 units/ml. We thus chose daily administration of multiple repeated dose for inpatients. To prevent withdrawal from the therapy as a result of untolerable adverse effects, the daily dose was set at 1 X 10(6) units, and rIL2 was given to 12 patients with metastatic renal cell carcinoma. Two-hour intravenous drip infusions containing 5 X 10(5) units of rIL2 was given daily 2 times to inpatients and after at least 28 days of this mode of administration, subcutaneous injection at a dose of 1 X 10(6) units was given 6 days a week to outpatients. Three patients showed complete response, 7 patients no change, and 2 patients progressive disease. Serious adverse effects due to capillary leak syndrome were not observed. We conclude that low-dose rIL2 is safe and has potential antitumor effects.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0042-1138
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
47 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
132-7
|
pubmed:dateRevised |
2006-10-30
|
pubmed:meshHeading |
pubmed-meshheading:1949370-Aged,
pubmed-meshheading:1949370-Carcinoma, Renal Cell,
pubmed-meshheading:1949370-Cytotoxicity, Immunologic,
pubmed-meshheading:1949370-Drug Administration Schedule,
pubmed-meshheading:1949370-Female,
pubmed-meshheading:1949370-Humans,
pubmed-meshheading:1949370-Immunotherapy, Adoptive,
pubmed-meshheading:1949370-Infusions, Intravenous,
pubmed-meshheading:1949370-Interleukin-2,
pubmed-meshheading:1949370-Kidney Neoplasms,
pubmed-meshheading:1949370-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:1949370-Male,
pubmed-meshheading:1949370-Middle Aged,
pubmed-meshheading:1949370-Recombinant Proteins
|
pubmed:year |
1991
|
pubmed:articleTitle |
Antitumor effects of interleukin 2 against renal cell carcinoma: basic study and clinical application.
|
pubmed:affiliation |
Department of Urology, School of Medicine, Keio University, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article
|